Italia markets close in 1 hour 45 minutes

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
222,27+1,17 (+0,53%)
Al 9:45AM EDT. Mercato aperto.
Accedi per pubblicare un messaggio.
  • M
    Mr. Iacobucci
    $AMWL conversation
    So undervalue stocks. I'm buying $AMWL $TDOC and $VRTX
  • N
    New
    Vertex Pharmaceuticals Incorporated
    I don't understand what Mr Market is doing with this stock. Great product. Market leader in CF. Highly profitable with a more diversified pipeline of drugs. Working closely with CRSPR. There's no reason why this stock is not having any momentum. Wallstreet bets should YOLO $VRTX and crush the shorts
  • s
    stocktargetadvisor
    $VRTX conversation
    $VRTX
    Upgrades Robert W Baird Outperform USD 220 » USD 252
  • V
    VirginiaLova
    $CRSP conversation
    $CRSP ties to $VRTX strengthen. Meanwhile, another red flag 🚩 at $EDIT — https://www.fiercebiotech.com/biotech/after-ditching-editas-abbvie-taps-caribou-for-new-crispr-car-t-pact
  • V
    VirginiaLova
    $CRSP conversation
    CRSP — THE $VRTX Q4 CONFERENCE CALL REPLAY is a must listen. Link? Link below! (Select “Listen to Webcast,” submit your information). One the presentation starts, feel free to jump to the 4-7 min mark of the presentation. The statements from the CEO Are absolutely FANTASTIC. https://investors.vrtx.com/events/event-details/vertex-pharmaceuticals-fourth-quarter-2020-earnings-conference-call

    Today, Elon Musk said CRSP is the future of medicine (laughing and saying you could turn yourself into a butterfly — he clearly watched the movie Human Nature). This is it. It is $CRSP
    The Investor Relations website contains information about Vertex Pharmaceuticals's business for stockholders, potential investors, and financial analysts.
    The Investor Relations website contains information about Vertex Pharmaceuticals's business for stockholders, potential investors, and financial analysts.
    investors.vrtx.com
  • t
    thirdmeinvestor
    $VRTX conversation
    $VRTX is one of the 15 most undervalued stock in SP 500 with 2021 P/E of 18.8.

    https://www.barrons.com/articles/15-undervalued-stocks-with-strong-earnings-growth-in-2021-51612569740
  • a
    ageninrussia
    $VRTX CEO: We are looking for “mid to late-stage" assets to buy.

    Please approach garo
  • E
    End Game
    $NVAX conversation
    Going to bring the new Board Member to the focus. Personally, what is the value to the comapny. As an investor we have no say, we really don't. But we can try to understand if there's a value for anything that is done that affects or effects our investments.

    So for Margaret G. McGlynn, R. Ph.

    From public records here's what I"ve found and my opine,

    1983 -2009 26 yrs Merck marketing,sales and managed care roles
    2005-2009 President Global Vaccines and Infectious diseases, Merck and
    2009 Amicus Theraputics Board for Air Products and Chemicals, mational Industrial Advisory Committee for Buffalo School of Pharmacy and a member of the Global Alliance for Vaccine Immunization (GAVI) Board

    GAVI
    Geneva, 7 August 2020 – A new landmark collaboration between SII, the world’s largest vaccine manufacturer by volume, Gavi and the Bill & Melinda Gates Foundation will accelerate the manufacture and delivery of up to 100 million doses of COVID-19 vaccines for low- and middle-income countries (LMICs) as part of the Gavi COVAX AMC, a mechanism within the COVAX Facility.

    Period between 2009 and 2016 International AIDS Vaccine Initiative
    2016 HCU Network America Non-profit
    Current Vertex Pharm and Novavax Boards

    She recieved 7700 shares/$140 persh 1,078,000

    Current public assets
    $FOLD 27,919 shares = $615,893
    $VRTX 877 shares = $196,448
    $NVAX 7700 = $885,500

    My personal opinion,
    The most recent expereince is down the Low/Middle low income countries through GAVI and the Non-Profits she has either started or been part of. Non-profits I hope is where we aren;t going to be concentrating the NVAX efforts. I"ve done a few jobs for non-profits. Very tough budget minded people. Her last Merck experience was 2009, 11 years ago That's a far stretch for reaching back for an M&A attempt by Merk. For the last 4 years, 2005-2009 she was the President global vaccines and infectious disease.

    I hope we see the real value her. A real M&A expert, or gov't FDA expert of getting FDA approvals to help the company get past this and to get the nanoFlu and RSV through the processes.
  • V
    VirginiaLova
    $VRTX conversation
    HUGE NEWS IN EARNINGS RELEASE FOR $CRSP. $CRSP $VRTX — CRISPR CEO “We are now progressing five cell therapy clinical trials in parallel targeting hemoglobinopathies and various cancers” and they have enrolled more patients in the CTX001 trials
  • T
    Tad
    $ARWR conversation
    from twitter: 43s
    $VRTX Citi boosts PT to $325. 2020 guidance is for $5.3B to $5.6B of product sales. Makes me think of mere $3B market cap for $ARWR and what will happen if/when they report POC in CF (and opens door to other lung indications)...

    know what you own
  • b
    bug
    Arrowhead Pharmaceuticals, Inc.
    We have certainly talked about this a lot but I continue to side eye $VRTX as to their approach on not only an approvable end point but how they propose to get there. Below is a comment from Reshma Kewalramani on the last CC

    "'Ive said a number of times previously, the companies that make augmentation therapy. About 5 of them have gotten their approvals in the U.S. based on levels of AAT. And so we need to go through that. Separately, we are very interested in, and I'm sure others might be interested in understanding the impact of our small molecule correctors on lung function measured by imaging or something like a pulmonary function test, and those are all considerations that we continue to talk and think about. But the framework for our package really is functional AAT levels, antigenic AAT levels and the clearance of the polymers from the liver".

    1) As mentioned augmentation therapy already exists. 2) If they were going to attempt to go the augmentation approval endpoint route, FDA would need to see clear benefit of the corrector over that SOC. Personal opinion, I don't see it showing substantiating improvement....why? the corrector by design has to perform multiple biologic complexity's just to turn the protein into what Augmentation therapy already is, a functional protein. Then is it safely correcting enough to be clinically significant. Sure augmentation therapy does nothing for the liver disease, but RNAi does with superb result at this point in time. I am by no means out to trash VRTX here just pointing out it appears their approach to this target is not only not competitive but I am viewing it as a lack of resources and a character flaw to their organization for continuing down this rabbit hole....for what?
  • V
    VirginiaLova
    $CRSP conversation
    Crispr Therapeutics initiated with a Buy at SunTrust SunTrust CRSP
    Crispr Therapeutics initiated with a Buy at SunTrust SunTrust CRSP
    thefly.com
  • V
    VirginiaLova
    $CRSP conversation
    Excited about the Suntrust upgrade. The analyst is a medical doctor. The Car - T program, as she noted, has not been priced into the stock. Her $140 target is low. Crsp, per Ceo, uses healthy donor cells, then does the edits to those cells using Crispr/ Cas9. The cancer treatments are then available “off the shelf” to be delivered to patients. This is critical for those with illness who need instant treatment. $CRSP wholly owns the Car-t program. $VRTX is partnered on most of the other developmental programs, including DMD. At any rate, the analyst from Suntrust is giving a price target, that when hit will be raised. I think the other analysts will be raising price targets soon too.
  • K
    Kim
    $SRPT conversation
    FromSY investing:
    Cantor 2020 #biotech outlook

    Top picks:
    - Large-cap: $VRTX $AMGN
    - Mid-cap: $SRPT $ALNY
    - Small-cap: $TGTX $ICPT $GBT $AGIO
    - Favorite binary: $MYOK
  • t
    thirdmeinvestor
    $VRTX conversation
    $VRTX and $BMRN stocks are downgraded to equal-weight from overweight by Morgan Stanley. Biotech analyst at MS is good, but very conservative in their rating. Their target price is 300. If I have to guess, we can reach 350 by January.
  • T
    Thirdmeinvestor
    $VRTX conversation
    $VRTX made to the list of [Barron’s 100 Most Sustainable Companies] (= Barrons' Cover story). Only a few biotech companies belong to the group.
  • V
    VirginiaLova
    $CRSP conversation
    Alexion Pharmaceuticals (ALXN) – Alexion agreed to be bought by AstraZeneca (AZN) in a $39 billion cash-and-stock deal valued at $175 per share, compared to Alexion’s Friday close of $120.98. The move will help expand AstraZeneca’s presence in treatments for rare diseases. Alexion shares surged 32% in premarket trading. $CRSP $VRTX $ARKG
  • V
    VirginiaLova
    $CRSP conversation
    Since receiving a landmark treatment with the gene-editing tool CRISPR, a sickle cell patient has the strength to care for herself and her children — while navigating the pandemic.
    Since receiving a landmark treatment with the gene-editing tool CRISPR, a sickle cell patient has the strength to care for herself and her children — while navigating the pandemic.
    www.npr.org
  • T
    Thirdmeinvestor
    $VRTX conversation
    My price target for $VRTX is 500. Progress both in business and drug development is impressive. Don't miss out the progress being made in CRISPR technology:

    https://www.investors.com/news/technology/crispr-gene-editing-biotech-companies/?src=A00220&yptr=yahoo

    Who said the lightening doesn't strike the same spot twice.
    Three small biotech stocks are at the forefront of a cheaper, faster gene editing method that could advance personalized medicine and cure thousands of diseases.
    Three small biotech stocks are at the forefront of a cheaper, faster gene editing method that could advance personalized medicine and cure thousands of diseases.
    www.investors.com
  • B
    Boru
    $ARWR conversation
    If $VRTX loses $11 billion in market cap (based on before hours trading), Shouldn't $ARWR gain at least $10 billion in market cap? That would make $ARWR's share price north of $100! But since this is $ARWR, it probably will end down today.